Dabrafenib is a selective inhibitor of BRAF, a proto-oncogene. It is primarily used for the treatment of late-stage melanoma.
|Mechanism of Action||Dabrafenib is a reversible and potent adenosine triphosphate-competitive inhibitor that selectively inhibits the BRAFV600E kinase.|
|References||Murali, R., M., & Long, G. (2012). Dabrafenib and its potential for the treatment of metastatic melanoma. DDDT Drug Design, Development and Therapy, 391. doi:10.2147/dddt.s38998|